Neurodevelopment and Neuroimaging in Parenterally-fed Infants and Young Children
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Manganese (Mn) is an essential metal required for normal growth and development. However, exposure to high Mn levels can be toxic to the brain. The objectives of this project are to identify neonatal and young pediatric populations that are at increased risk of excessive brain Mn deposition and altered cognitive and motor development based on their dietary parenteral Mn exposure, and to make sound and evidence-based recommendations for appropriate Mn supplementation and monitoring of infants and young children receiving parenteral nutrition (PN). Our studies are designed to test the hypotheses that, compared with unexposed age-matched controls, infants and young children receiving prolonged Mn-supplemented PN will have increased deposition of Mn in their brains and lower scores on neurodevelopmental, cognitive and psychophysiological assessments.
| Condition | Intervention |
|---|---|
|
Parenteral Nutrition Necrotizing Enterocolitis Digestive System Abnormalities Cholestasis |
Dietary Supplement: Remove Mn from PN if evidence of increased brain Mn on MRI |
| Study Type: | Observational |
| Study Design: | Time Perspective: Prospective |
| Official Title: | Neurodevelopment and Neuroimaging in Parenterally-fed Infants and Young Children |
Blood
| Enrollment: | 122 |
| Study Start Date: | August 2006 |
| Study Completion Date: | December 2010 |
| Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
1
Preterm infants in NICU and age-matched controls
|
Dietary Supplement: Remove Mn from PN if evidence of increased brain Mn on MRI
Withhold Mn-containing trace element cocktail and add zinc, copper and chromium individually to PN
|
|
2
Term infants in NICU and age-matched controls
|
Dietary Supplement: Remove Mn from PN if evidence of increased brain Mn on MRI
Withhold Mn-containing trace element cocktail and add zinc, copper and chromium individually to PN
|
|
3
Children on home PN (to age 6) and age-matched controls
|
Dietary Supplement: Remove Mn from PN if evidence of increased brain Mn on MRI
Withhold Mn-containing trace element cocktail and add zinc, copper and chromium individually to PN
|
Detailed Description:
Specific Aims have been designed to test these hypotheses in three developmentally distinct populations:
- preterm infants and
- full term infants in the Neonatal Intensive Care Unit (NICU) requiring prolonged PN and
- older infants and young children on home PN.
Mn neurotoxicity will be investigated by longitudinal assessments of cognitive (executive functioning battery), neurodevelopmental (Bayley III Scales of Infant Development), and psychophysiological (event-related potential) measures and will be correlated with brain deposition of Mn using the technique of magnetic resonance (MR) relaxometry in a vulnerable population of infants receiving Mn-supplemented PN and age-matched controls. This proposal addresses a clinically relevant and unexplored link between nutritional practices, brain Mn deposition and neurodevelopmental sequelae in an at-risk population of infants and young children utilizing state-of-the-art magnetic resonance imaging (MRI) technology and neurodevelopmental assessment techniques. The potential for increased brain Mn accumulation in infants, and by inference, the potential health risks associated with elevated brain Mn burden, represents crucial, unexplored issues of exposure and susceptibility. The potential contribution of Mn toxicity to the poor outcomes of infants dependent for an extended time on PN has not been fully acknowledged or studied. Improved understanding of the relationships between Mn exposure and developmental outcomes will undoubtedly lead to altered clinical practices and more careful monitoring of Mn intake and blood and/or brain Mn levels in high risk infants. Our studies will also contribute to an improved understanding of the value of non-invasive MR imaging in the monitoring of pediatric patients on PN.
Eligibility| Ages Eligible for Study: | up to 6 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Term and preterm infants on prolonged PN in the NICU and post-discharge and young children on home PN and age-matched controls
Inclusion Criteria:
- Greater than 30 days postnatal age
- In the preceding four weeks, have received >75% of their nutrition as Mn-supplemented PN
- Clinically stable for transport to the MR facility
- Signed parental consent.
Or healthy age-matched controls
Exclusion Criteria:
- Any infant not expected to survive to the age of 3 months or
- Not expected to achieve sufficient clinical stability to tolerate the MRI procedure.
Contacts and Locations| United States, Tennessee | |
| Vanderbilt Children's Hospital | |
| Nashville, Tennessee, United States, 37232-9544 | |
| Principal Investigator: | Judy L Aschner, MD | Vanderbilt University |
More Information
Publications:
| Responsible Party: | Judy L. Aschner, MD, Vanderbilt University Medical Center |
| ClinicalTrials.gov Identifier: | NCT00392730 History of Changes |
| Other Study ID Numbers: | Gerber07-01-06JLA, ES013730 |
| Study First Received: | October 25, 2006 |
| Last Updated: | March 29, 2011 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Vanderbilt University:
|
Manganese Neonatal Intensive Care MRI Parenteral Nutrition Prematurity |
Additional relevant MeSH terms:
|
Congenital Abnormalities Cholestasis Enterocolitis Digestive System Abnormalities Enterocolitis, Necrotizing Bile Duct Diseases |
Biliary Tract Diseases Digestive System Diseases Gastroenteritis Gastrointestinal Diseases Intestinal Diseases |
ClinicalTrials.gov processed this record on June 17, 2013